In the past 52-week period, shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have moved within the range of $2.20 to $3.97. On the stock’s most recent trading day, the company’s shares ended the regular session at $2.86, which is 27.96% higher than its 52-week high.
Celldex Therapeutics, Inc. (CLDX) has demonstrated a 20-day simple moving average (SMA) of -2.49%, and a 50-day SMA of 0.71%. This public company’s current market capitalization stands at $391.51 million.Analyzing Consensus Estimates, Sales Revenue and Net Income
Gauging the level of enthusiasm that Wall Street analysts have for a particular stock is important when considering an investment. According to the latest data, the consensus recommendation for Celldex Therapeutics, Inc. (CLDX) is Outperform.
When it comes to reporting sales figures, public companies typically post earnings and revenue that fall above or below the average Wall Street forecast. In the most recent quarterly financial report, for the quarter ending Sep. 2017, Celldex Therapeutics, Inc. (CLDX) delivered a 259.93% surprise with its net revenue.
Meanwhile, during the same quarter Celldex Therapeutics, Inc. (CLDX) delivered a -24.53% earnings surprise. Net earnings for the quarter were posted at -$0.20 per share, whereas Wall Street had forecast -$0.26 per share.Ownership at Celldex Therapeutics, Inc. (CLDX), According to Most Recent SEC Filings
A publicly-traded company’s most recent 13F filings give us important details about the organization’s institutional ownership. Celldex Therapeutics, Inc. (CLDX) has 0 billion shares outstanding currently, 52.47% of which belong to institutional investors. Those institutional holdings amount to $0.2 billion.
Additionally, according to the most recent 13F filing from Celldex Therapeutics, Inc. (CLDX), there were 18 new positions totaling 1,730,262 shares of the company’s stock. There were 15 sold out positions, on the other hand, totaling 332,643 shares.Short, Medium and Long Term Indicators
Taking a look at a stock’s average volume – in the long, medium and short terms – is helpful for understanding investor sentiment and trading activity. Celldex Therapeutics, Inc. (CLDX) has had a 20-day average volume of 1,207,750 shares, with an average of 40% of short term indicators pointed at Sell.
The stock’s 50-day average volume has been 1,172,756 shares, with an average of 0% of medium term indicators pointing toward Hold. Finally, its 100-day average volume is 1,346,027 shares with 67% of long-term indicators pointing to Buy.